Neonatal Immune In Vitro Model for Vaccine Efficacy Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The clinical development of vaccines is hindered by the lack of appropriate in vitro assays for testing immune responses in immature immune systems, particularly in neonates, as current models fail to accurately replicate early life immune responses.
Innovation Solution
Development of mammalian umbilical cord blood-based neonatal modular immune in vitro construct (nMIMIC) models that mimic the neonatal immune system, incorporating cord blood-derived T, B, and dendritic cells to predict early life immune responses and assess vaccine efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current in vitro models are used for testing immune responses, then general immune system testing is possible, but accurate replication of neonatal immune responses cannot be achieved
Solution Approach 1:
The patent creates a biomimetic in vitro model that copies the neonatal immune system by using cord blood-derived cells (T cells, B cells, dendritic cells) to replicate the actual neonatal immune response in a controlled laboratory setting, thereby achieving accurate measurement of neonatal immune responses without needing to test on actual neonates
Solution Approach 2:
The model changes the parameters of the immune system being studied by specifically selecting and culturing neonatal cord blood cells with particular ratios of T cells, B cells, and dendritic cells, and by controlling culture conditions to mimic the neonatal immune environment, thereby enabling accurate replication of neonatal-specific immune responses
2Measurement precision
If clinical trials are conducted to assess vaccine immunogenicity in neonates, then accurate immune response data can be obtained, but the process becomes time-consuming and costly
Solution Approach 1:
The patent creates a biomimetic in vitro model that copies the neonatal immune system by using cord blood-derived cells (T cells, B cells, dendritic cells) to replicate the actual neonatal immune response in a controlled laboratory setting, thereby achieving accurate measurement of neonatal immune responses without needing to test on actual neonates
Solution Approach 2:
The model performs preliminary testing of vaccine candidates in vitro using neonatal cord blood cells before actual clinical trials, allowing researchers to screen and evaluate vaccine immunogenicity in advance, thereby reducing the time and resources needed for subsequent clinical testing
Data Source
Figure 1
Figure 2
Figure 3
AI summary
In vitro biomimetic models of the neonatal immune system are provided along with methods of using the models in pre-clinical assessment of infant immune cell-mediated and humoral responses to immunogenic stimulation, such as vaccination. The models include one comprising cord blood-derived T follicular helper cells and B cells, and one comprising cord blood-derived dendritic cells and CD4+ T cells. The models can be used, for example, to assess candidate vaccines via analysis of cellular responses to antigen and vaccine exposure.